ImmuONE
Specialised translational approaches and in vitro testing services
Specialised translational approaches and in vitro testing services
ImmuONE is a United Kingdom-based startup founded in 2019 that specializes in human alveolar macrophage responses, epithelial cell culture platforms, and testing services. The company's respiratory tissue models closely resemble lung physiology, providing relevant, reliable, and reproducible results for inhalation safety assessments. ImmuONE has received a notable £2.00MSeed Round investment on 25 October 2023 from MEIF Proof-of-Concept & Early Stage Fund, Pioneer Group, and Mercia’s EIS funds. It is actively involved in developing sustainable technologies in partnership with industry and academia to support human-relevant safety assessments and develop animal product-free cell models. ImmuONE offers a range of standard and bespoke assessments for inhalation safety and invites businesses to explore their innovative solutions for inhalation toxicology, irritation sensitization, alveolar clearance, and inflammation. To know more, visit the startup's website at www.immuone.com and follow them on Twitter @ImmuONE.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | £2.00M | 3 |
|
25 Oct 2023 |
No recent news or press coverage available for ImmuONE.
We care about your data, and we'd love to use cookies make your experience better.
